scholarly article | Q13442814 |
P356 | DOI | 10.1007/978-3-319-24223-1_8 |
P698 | PubMed publication ID | 26667343 |
P2093 | author name string | Alexander Drilon | |
Jarushka Naidoo | |||
P2860 | cites work | The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants | Q24317051 |
The structural basis of the activation of Ras by Sos | Q24320225 | ||
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers | Q24611043 | ||
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene | Q24647664 | ||
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis | Q24650902 | ||
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy | Q27313799 | ||
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy | Q27824765 | ||
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma | Q27851448 | ||
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations | Q27851664 | ||
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response | Q27851728 | ||
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 | ||
KRAS mutations in non-small cell lung cancer | Q28240568 | ||
RAS oncogenes: weaving a tumorigenic web | Q28250360 | ||
Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort | Q57419582 | ||
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype | Q61899364 | ||
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung | Q68532141 | ||
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient | Q71265374 | ||
Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer | Q74611887 | ||
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer | Q79317427 | ||
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models | Q80352305 | ||
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers | Q81001986 | ||
Comprehensive genomic characterization of squamous cell lung cancers | Q28274701 | ||
Ras oncogenes: split personalities | Q29615405 | ||
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 | Q29617043 | ||
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial | Q33521023 | ||
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. | Q33561943 | ||
Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas | Q33563803 | ||
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications | Q33899708 | ||
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study | Q33969308 | ||
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. | Q34124421 | ||
Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability | Q34193618 | ||
The role of proteasome inhibition in nonsmall cell lung cancer | Q35001441 | ||
Development of farnesyl transferase inhibitors: a review | Q36263983 | ||
RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas | Q36763119 | ||
KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma | Q37067360 | ||
The potential role of mTOR inhibitors in non-small cell lung cancer | Q37096395 | ||
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 | ||
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma | Q37428076 | ||
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy | Q38048579 | ||
KRAS mutations in lung cancer | Q38057476 | ||
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma | Q38256553 | ||
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. | Q38409218 | ||
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies | Q39213209 | ||
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib | Q39271324 | ||
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition | Q39606314 | ||
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras | Q39991720 | ||
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer | Q40591213 | ||
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens | Q42673662 | ||
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer | Q43184359 | ||
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation | Q44242530 | ||
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer | Q44425380 | ||
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. | Q45917382 | ||
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study | Q46213605 | ||
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. | Q46484712 | ||
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 | ||
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer | Q46892013 | ||
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer | Q47992122 | ||
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma | Q48021940 | ||
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. | Q54771804 | ||
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 155-178 | |
P577 | publication date | 2016-01-01 | |
P1433 | published in | Advances in Experimental Medicine and Biology | Q4686385 |
P1476 | title | KRAS-Mutant Lung Cancers in the Era of Targeted Therapy | |
P478 | volume | 893 |
Q50109671 | Cancer Susceptibility Models in Protease-Deficient Mice |
Q47123664 | Effects of Resveratrol against Lung Cancer: In Vitro and In Vivo Studies |
Q38729111 | ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology |
Q43465454 | Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers |
Q46406409 | Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression |
Q33737286 | Inhibition of Human Lung Cancer Cell Proliferation and Survival by Post-Exercise Serum Is Associated with the Inhibition of Akt, mTOR, p70 S6K, and Erk1/2. |
Q100634054 | KRAS K104 modification affects the KRASG12D-GEF interaction and mediates cell growth and motility |
Q39290525 | Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies |
Q43100869 | Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma |
Q36134534 | Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR. |
Q38792903 | P21, COX-2, and E-cadherin are potential prognostic factors for esophageal squamous cell carcinoma |
Q91689376 | Precision oncology in Latin America: current situation, challenges and perspectives |
Q92530669 | Role of KRAS in regulating normal human airway basal cell differentiation |